Median progression-free survival was 9.7 months (95% confidence interval [CI] 7.2-12.3) compared to 4.7 months (95% CI 4.3-5.1) (P < .001) for IDH-wildtype glioblastoma patients in the population-based reference cohort 1. The gene discussed is IDH1; the disease is glioblastoma.